ArticleScientific reports2015
Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Functional Gene Expression Differentiation of the Notch Signaling Pathway in Female Reproductive Tract Tissues-A Comprehensive Review With Analysis.Frontiers in cell and developmental biology · 2020Pooled it
- Anticancer Effect of Pacificusoside D from the StarfishMarine drugs · 2026Article
- IGCN: integrative graph convolution networks for patient level insights and biomarker discovery in multi-omics integration.Bioinformatics (Oxford, England) · 2025Article
- Clinically SignificantCancers · 2024Article
- Undetected αKlotho in serum is associated with the most aggressive phenotype of breast cancer.Molecular and clinical oncology · 2022Article
- A "NOTCH" Deeper into the Epithelial-To-Mesenchymal Transition (EMT) Program in Breast Cancer.Genes · 2019Review
- Extracting predictors for lung adenocarcinoma based on Granger causality test and stepwise character selection.BMC bioinformatics · 2019Article
- FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally SuppressingInternational journal of biological sciences · 2019Article
- Article
- Use of DAVID algorithms for clustering custom annotated gene lists in a non-model organism, rainbow trout.BMC research notes · 2018Article
- Moving Breast Cancer Therapy up a Notch.Frontiers in oncology · 2018Review
- Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer.Nature communications · 2017Article
- Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!Biochimica et biophysica acta. Reviews on cancer · 2017Review
- A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.Scientific reports · 2017Article
- Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer.Scientific reports · 2017Article
- Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort.Saudi medical journal · 2017Article
- Circular RNAs and their associations with breast cancer subtypes.Oncotarget · 2016Article
- Progress in the clinical detection of heterogeneity in breast cancer.Cancer medicine · 2016Review
- Exploring the intrinsic differences among breast tumor subtypes defined using immunohistochemistry markers based on the decision tree.Scientific reports · 2016Article
- Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.Breast cancer research and treatment · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is highly heterogeneous. The subtypes defined using immunohistochemistry markers and gene expression profilings (GEP) are related but not equivalent, with inter-connections under investigated. Our previous study revealed a set of differentially expressed genes (diff-genes), containing 1015 mRNAs and 69 miRNAs, which characterize the immunohistochemistry-defined breast tumor subtypes at the GEP level. However, they may convey redundant information due to the large amount of genes included. By reducing the dimension of the diff-genes, we identified 119 mRNAs and 20 miRNAs best explaining breast tumor heterogeneity with the most succinct number of genes found using hierarchical clustering and nearest-to-center principle. The final signature panel contains 119 mRNAs, whose superiority over diff-genes was replicated in two independent public datasets. The comparison of our signature with two pioneering signatures, the Sorlie's signature and PAM50, suggests a novel marker, FOXA1, in breast cancer classification. Subtype-specific feature genes are reported to characterize each immunohistochemistry-defined subgroup. Pathway and network analysis reveal the critical roles of Notch signalings in [ER+|PR+]HER2- and cell cycle in [ER+|PR+]HER2+ tumors. Our study reveals the primary differences among the four immunohistochemistry-defined breast tumors at the mRNA and miRNA levels, and proposes a novel signature for breast tumor subtyping given GEP data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.